文献速递乳房整形与再造美容整形

白三烯拮抗剂抑制假体乳房术后包膜挛缩的荟萃分析

Suppressive Effect of Leukotriene Antagonists on Capsular Contracture in Patients Who Underwent Breast Surgery with Prosthesis: A Meta-Analysis.
PubMed 文献 · Plast Reconstr Surg · 2020-01-01

该荟萃分析纳入5项临床研究、1710例假体植入,评估白三烯拮抗剂对乳房假体术后包膜挛缩的治疗与预防作用。结果显示白三烯拮抗剂显著抑制包膜挛缩形成(合并风险差0.84,95%CI 0.79–0.89),孟鲁司特和扎鲁司特亚组均有效。

要点

  • 白三烯拮抗剂可显著抑制乳房假体术后包膜挛缩形成。
  • 孟鲁司特与扎鲁司特亚组均显示抑制包膜挛缩有效。
  • 用药需合理安全,疗效、疗程与机制仍需进一步研究。

核心结论

  • 白三烯拮抗剂(孟鲁司特和扎鲁司特)对治疗和预防包膜挛缩有显著效果。

研究设计与样本

  • 荟萃分析,检索中英文数据库,纳入评估白三烯拮抗剂对乳房假体植入后包膜挛缩疗效与预防作用的临床研究。
  • 共纳入5项合格研究,涉及1710例乳房假体植入。
  • 采用风险差及95%置信区间作为最终合并统计量。

主要发现

  • 白三烯拮抗剂显著抑制包膜挛缩形成,统计学显著水平为32.02(p < 0.001),合并风险差0.84(95%CI 0.79–0.89)。
  • 孟鲁司特亚组合并统计水平19.34(p < 0.001),合并风险差0.83(95%CI 0.75–0.92)。
  • 扎鲁司特亚组合并统计水平79.48(p < 0.001),合并风险差0.85(95%CI 0.83–0.87)。

临床怎么用

  • 对假体乳房手术患者,可考虑合理安全地使用白三烯拮抗剂以抑制包膜挛缩。

局限性

  • 白三烯拮抗剂治疗假体周围包膜挛缩的临床疗效、疗程、安全性和确切机制仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Capsular contracture is a troublesome and distressing complication in mammaplasty or breast reconstruction involving a prosthesis. Previous studies have indicated that leukotriene antagonists effectively reverse capsular contracture. However, this treatment method lacks comprehensive support from evidence-based medicine and remains considerably controversial. In this study, a meta-analysis was conducted to evaluate the therapeutic and preventive effects of leukotriene antagonists on capsular contracture in patients after breast prosthesis implantation. METHODS: A comprehensive literature search was performed in English and Chinese databases. All clinical studies assessing the therapeutic and prophylactic effects of leukotriene antagonists on capsule contracture after breast prosthesis implantation were selected. Risk differences and 95 percent confidence intervals were applied as the final pooled statistics. RESULTS: A total of five eligible studies were included, involving 1710 breast prosthesis implantations. The final results indicated that leukotriene antagonists markedly inhibited capsular contracture formation, with statistical significance at 32.02 (p < 0.001) (pooled risk difference, 0.84; 95 percent CI, 0.79 to 0.89). In subgroup analysis, subgroups based on different leukotriene antagonists included the montelukast and zafirlukast groups, with significant pooled statistical levels of 19.34 (p < 0.001) and 79.48 (p < 0.001), respectively (montelukast: pooled risk difference, 0.83; 95 percent CI, 0.75 to 0.92; zafirlukast: pooled risk difference, 0.85; 95 percent CI, 0.83 to 0.87), indicating that both montelukast and zafirlukast were effective in inhibiting encapsulation. CONCLUSIONS: This meta-analysis demonstrated that leukotriene antagonists (montelukast and zafirlukast) have significant effects in treating and preventing capsular contracture. These medications should be administered in a reasonable and safe way. Further studies of clinical efficacy, duration, safety, and exact mechanism of leukotriene antagonists for periprosthetic capsular contracture are warranted.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Wang Y, Tian J, Liu J, et al. Suppressive Effect of Leukotriene Antagonists on Capsular Contracture in Patients Who Underwent Breast Surgery with Prosthesis: A Meta-Analysis. Plast Reconstr Surg. 2020. PMID: 32221199. doi:10.1097/PRS.0000000000006629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。